| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neural and Behavior Sciences (Drs. Connor, Wang, and Patton, S.L. Menzies), Penn State College of Medicine, Hershey, PA; and Departments of Pathology (Dr. Troncoso) and Neurology (Drs. Earley and Allen), Johns Hopkins University, Baltimore, MD.
Address correspondence and reprint requests to Dr. James R. Connor, Department of Neural and Behavioral Sciences (H109), G.M. Leader Family Laboratory for AD Research, Penn State College of Medicine, 500 University Drive, Hershey, PA 17033; e-mail: jrc3{at}psu.edu
Background: Restless legs syndrome (RLS) is a sensory-movement disorder affecting 5 to 10% of the population. Its etiology is unknown, but MRI analyses and immunohistochemical studies on autopsy tissue suggest the substantia nigra (SN) of patients with RLS has subnormal amounts of iron.
Methods: Neuromelanin cells from the SN of four RLS and four control brains were isolated by laser capture microdissection, and a profile of iron-management protein expression was obtained by immunoblot analysis. Binding assays for iron regulatory protein activity were performed on cell homogenates.
Results: Ferritin, divalent metal transporter 1, ferroportin, and transferrin receptor (TfR) were decreased in RLS neuromelanin cells compared with control. Transferrin was increased in RLS neuromelanin cells. This protein profile in RLS neuromelanin cells is consistent with iron deficiency with the exception that TfR expression was decreased rather than increased. The concentration and activity of the iron regulatory proteins (IRP1 and IRP2) were analyzed to determine whether there was a functional deficit in the post-transcriptional regulatory mechanism for TfR expression. Total IRP activity, IRP1 activity, and IRP1 protein levels were decreased in RLS, but total IRP2 protein levels were not decreased in RLS.
Conclusion: Restless legs syndrome may result from a defect in iron regulatory protein 1 in neuromelanin cells that promotes destabilization of the transferrin receptor mRNA, leading to cellular iron deficiency.
Received August 28, 2003. Accepted in final form December 30, 2003.
This article has been cited by other articles:
|
|
 |
|
  L. G. Astrakas, S. Konitsiotis, P. Margariti, S. Tsouli, L. Tzarouhi, and M. I. Argyropoulou T2 relaxometry and fMRI of the brain in late-onset restless legs syndrome Neurology, September 16, 2008; 71(12): 911 - 916. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Starn and J. N. Udall JR Iron Deficiency Anemia, Pica, and Restless Legs Syndrome in a Teenage Girl Clinical Pediatrics, February 1, 2008; 47(1): 83 - 85. [PDF]
|
|
|
|
 |
|
 C. E. Gamaldo and C. J. Earley Restless legs syndrome: a clinical update. Chest, November 1, 2006; 130(5): 1596 - 1604. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Bogan, J. M. Fry, M. H. Schmidt, S. W. Carson, S. Y. Ritchie, and TREAT RLS US (Therapy with Ropinirole Efficacy And Ropinirole in the Treatment of Patients With Restless Legs Syndrome: A US-Based Randomized, Double-Blind, Placebo-Controlled Clinical Trial Mayo Clin. Proc., January 1, 2006; 81(1): 17 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Hogl, S. Kiechl, J. Willeit, M. Saletu, B. Frauscher, K. Seppi, J. Muller, G. Rungger, A. Gasperi, G. Wenning, et al. Restless legs syndrome: A community-based study of prevalence, severity, and risk factors Neurology, June 14, 2005; 64(11): 1920 - 1924. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Deceased.